Infections WHO grade 2-4 after intermediate-dose melphalan (IDM) cycles I and II (%) and myeloablative treatment
| . | Treatment period . | Myeloablative therapy, n = 104 . | |
|---|---|---|---|
| IDM cycle 1, n = 254 . | IDM cycle 2, n = 206 . | ||
| Septicemia | 9 | 8 | 41 |
| Lung | 6 | 4 | 15 |
| Ear/nose/throat | 7 | 5 | 10 |
| GI tract | 2 | 1 | 10 |
| GU tract | 2 | 1 | 2 |
| Mucosa | 5 | 2 | 10 |
| Skin | 7 | 9 | 15 |
| Fever | 8 | 10 | 22 |
| Other | 2 | 1 | 9 |
| Maximum WHO 2 | 18 | 17 | 30 |
| Maximum WHO 3 | 12 | 12 | 39 |
| Maximum WHO 4 | 1 | 1 | 5 |
| . | Treatment period . | Myeloablative therapy, n = 104 . | |
|---|---|---|---|
| IDM cycle 1, n = 254 . | IDM cycle 2, n = 206 . | ||
| Septicemia | 9 | 8 | 41 |
| Lung | 6 | 4 | 15 |
| Ear/nose/throat | 7 | 5 | 10 |
| GI tract | 2 | 1 | 10 |
| GU tract | 2 | 1 | 2 |
| Mucosa | 5 | 2 | 10 |
| Skin | 7 | 9 | 15 |
| Fever | 8 | 10 | 22 |
| Other | 2 | 1 | 9 |
| Maximum WHO 2 | 18 | 17 | 30 |
| Maximum WHO 3 | 12 | 12 | 39 |
| Maximum WHO 4 | 1 | 1 | 5 |
GI tract indicates gastrointestinal tract; and GU tract, genito-urethral tract.